Vasculitis Clinical Trials

100 recruitingLast updated: July 17, 2026

There are 100 actively recruiting vasculitis clinical trials across 32 countries. Studies span Phase 1, Phase 2, Early Phase 1, Phase 3, Phase 4, Not Applicable. Top locations include Paris, France, Philadelphia, Pennsylvania, United States, Cleveland, Ohio, United States. Updated daily from ClinicalTrials.gov.


Vasculitis Trials at a Glance

100 actively recruiting trials for vasculitis are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Phase 1 with 22 trials, with the heaviest enrollment activity in Paris, Philadelphia, and Cleveland. Lead sponsors running vasculitis studies include Assistance Publique - Hôpitaux de Paris, China Immunotech (Beijing) Biotechnology Co., Ltd., and University of Pennsylvania.

Browse vasculitis trials by phase

Treatments under study

About Vasculitis Clinical Trials

Looking for clinical trials for Vasculitis? There are currently 25 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Vasculitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Vasculitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 100 trials

Recruiting
Phase 4

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Amgen300 enrolled82 locationsNCT06072482
Recruiting

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

ANCA-associated VasculitisGiant Cell ArteritisTakayasu's Arteritis+2 more
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)4,000 enrolled1 locationNCT02257866
Recruiting
Phase 1

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

ANCA-associated VasculitisIgG4-Related DiseasesLupus Nephritis+1 more
Nanjing University School of Medicine24 enrolled1 locationNCT06285279
Recruiting

Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis

IgA NephropathyDiabetic NephropathiesANCA-associated Vasculitis+4 more
Assistance Publique - Hôpitaux de Paris146 enrolled1 locationNCT07010250
Recruiting
Phase 3

A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial

ANCA-associated VasculitisCrescentic GlomerulonephritisRapidly Progressive Glomerulonephritis
Assistance Publique - Hôpitaux de Paris126 enrolled25 locationsNCT05946564
Recruiting
Early Phase 1

MTS109 in Patients With Refractory Autoimmune Diseases

Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis (SSc)+2 more
Shanghai Changzheng Hospital15 enrolled1 locationNCT07526350
Recruiting
Not Applicable

Biocollection of Patients With ANCA Associated Vasculitis

ANCA-associated Vasculitis
University Hospital, Brest100 enrolled1 locationNCT05364892
Recruiting

I-FABP as a Predictor of Gastrointestinal Involvement in Pediatric IgA Vasculitis

IgA VasculitisGastrointestinal Involvement
Bursa City Hospital100 enrolled1 locationNCT07664228
Recruiting

Ocular Manifestations of Granulomatosis With Polyangiitis.

VasculitisMicroscopic Polyangiitis (MPA)Churg-Strauss Syndrome (CSS)+1 more
Military Institute od Medicine National Research Institute70 enrolled1 locationNCT07664709
Recruiting
Phase 3

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

Vasculitis
Amgen20 enrolled34 locationsNCT06321601
Recruiting
Phase 2

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.75 enrolled78 locationsNCT07160608
Recruiting

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

lichen planusAtopic DermatitisHidradenitis Suppurativa+9 more
Assistance Publique - Hôpitaux de Paris830 enrolled1 locationNCT06599411
Recruiting
Phase 1Phase 2

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

StrokeVasculitisAneurysm+1 more
University of California, San Francisco8 enrolled1 locationNCT02638701
Recruiting

EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases

PericarditisRheumatoid ArthritisSarcoidosis+10 more
Assistance Publique - Hôpitaux de Paris5,000 enrolled1 locationNCT07077304
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis+1 more
Nkarta, Inc.240 enrolled17 locationsNCT06733935
Recruiting
Phase 2

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

ANCA Associated Vasculitis (AAV)
Novartis Pharmaceuticals126 enrolled35 locationsNCT06868290
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled21 locationsNCT06308978
Recruiting
Phase 1Phase 2

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Marcela V. Maus, M.D.,Ph.D.12 enrolled1 locationNCT07388277
Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting

SysteMic vAsculitis pRognosis and ouTcome

Vasculitis
Fondazione IRCCS Policlinico San Matteo di Pavia300 enrolled1 locationNCT07586137